Simple quantitative assessment for repigmentation in vitiligo.

Int J Dermatol. 2012 Mar;51(3):360-1

Authors: Sohail A, Vaqas B, Bodeker G, Ryan T

PMID: 22348581 [PubMed - in process]

Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-β) in patients with vitiligo.

J Am Acad Dermatol. 2012 Mar;66(3):510-1

Authors: Khan R, Gupta S, Sharma A

PMID: 22342018 [PubMed - in process]

Photolichenoid plaques with associated vitiliginous pigmentary changes.

Dermatol Online J. 2011;17(10):13

Authors: Tran K, Hartman R, Tzu J, Meehan S, Sanders SE, Pomeranz MK, Sanchez M

Abstract
A 49-year-old man with advanced HIV/AIDS on anti-retroviral therapy (HAART) and trimethoprim-sulfamethoxazole (TMP-SMX) presented with a several-month history of pruritic, erythematous, lichenified papules that coalesced into hyperkeratotic plaques on the trunk and extremities in a sun-exposed distribution. He shortly thereafter developed a progressive depigmentation over more than 80 percent of his body surface area. A biopsy specimen of an erythematous plaque on the trunk showed a superficial and mid-dermal infiltrate of lymphocytes with eosinophils, most consistent with either chronic lichenoid drug eruption or atypical lymphoproliferative disorder (ACLD) of HIV. The patient's lichenoid skin disease has persisted despite discontinuation of TMP-SMX, although it has improved partially with administration of topical glucocorticoids and acitretin. His depigmentation has continued to progress. We discuss the overlapping diagnostic entities which may be comprised by this patient's clinical disease, and highlight a unique presentation of the complex interaction between HIV infection and the skin.

PMID: 22031639 [PubMed - indexed for MEDLINE]